Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsabiv Switch Study in Hemodialysis Patients With Secondary Hyperparathyroidism
NCT01932970Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2013
- Primary completion
- Jan 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Started Aug 2013; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01932970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01932970.